A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

← catalyst calendar

NCT04866134 · readout in 74 d

Sponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

200estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-05-07

actual

When the study began enrolling

Primary completion

2026-11-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-01-01

estimated

The whole study's end, after follow-up

First posted

2021-04-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced or Metastatic Solid Tumors

Interventions

Drug: ERAS-007
Drug: ERAS-601

Primary outcomes

what the primary-completion date above is the date OF

Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW

measured Assessed up to 24 months from time of first dose

Dose Limiting Toxicities (DLT)